Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Icahn School of Medicine at Mount Sinai
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05879458CT.gov Ritlecitinib in CTCL | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sezary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ritlecitinib (this asset) | Icahn School of Medicine at Mount Sinai | P2 | CCC · 50 |
| Cyclophosphamide | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Prednisone | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| (+)-Vincristine | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Cyclosporin A | Ohio State University Comprehensive Cancer Center | P2 | BB |
| Mogamulizumab | Kyowa Kirin Co., Ltd. | P2 | B |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Vanderbilt University Medical Center | P4 | B |
| Denileukin Diftitox | Eisai Inc. | P4 | B |
| Brentuximab Vedotin | City of Hope Medical Center | P2 | B |
+32 more in the Sezary Syndrome cohort
Other indications for Ritlecitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Celiac Disease | — | P2 | CCC · 52 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P2 | CCC · 50 |
| Mycosis Fungoides | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ritlecitinib in Sezary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ritlecitinib-sezary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →